Benzinga | Aug 10, 2021 08:58AM EDT

Chardan Capital Maintains Buy on Dicerna Pharmaceuticals, Lowers Price Target to $28

Chardan Capital analyst Keay Nakae maintains Dicerna Pharmaceuticals (NASDAQ:DRNA) with a Buy and lowers the price target from $34 to $28.